ReviewThe pharmacogenomics journal2017
More than 25 years of genetic studies of clozapine-induced agranulocytosis.
Review in The pharmacogenomics journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Genetic risk of clozapine-induced leukopenia and neutropenia: a genome-wide association study.Translational psychiatry · 2021Pooled it
- Clozapine-related neutropenia and agranulocytosis in Korea: 2025 update for rethinking the role of monitoring system.Therapeutic advances in psychopharmacology · 2026Article
- Polygenic overlap with granulocyte counts identifies novel loci for clozapine metabolism and clozapine-induced agranulocytosis.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Article
- Immunomodulatory Effects of Clozapine: More Than Just a Side Effect in Schizophrenia.Current neuropharmacology · 2024Review
- De Novo Seizures, Obsessive Compulsive Symptoms and Neutropenias in Patients on Clozapine: A Retrospective Cohort Study.Indian journal of psychological medicine · 2023Article
- Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders.Translational psychiatry · 2022Article
- Patients' Experiences of Clozapine for Treatment-Resistant Schizophrenia: A Systematic Review.Schizophrenia bulletin open · 2022Article
- Clozapine rechallenge following neutropenia using granulocyte colony-stimulating factor: A Quebec case series.Journal of psychopharmacology (Oxford, England) · 2021Article
- Clinical Utility and Safety of Slower-than-Recommended Titration of Clozapine for Treatment-Resistant Schizophrenia: a Retrospective Cohort Study.The Psychiatric quarterly · 2021Article
- Clozapine re-challenge and initiation following neutropenia: a review and case series of 14 patients in a high-secure forensic hospital.Therapeutic advances in psychopharmacology · 2021Article
- Clozapine: An Updated Overview of Pharmacogenetic Biomarkers, Risks, and Safety-Particularities in the Context of COVID-19.Brain sciences · 2020Review
- Genetic associations with clozapine-induced myocarditis in patients with schizophrenia.Translational psychiatry · 2020Article
- Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine.The pharmacogenomics journal · 2019Article
- Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective.Pharmacogenomics · 2019Review
- Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine.Therapeutic advances in drug safety · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clozapine is one of the most effective atypical antipsychotic drugs prescribed to patients with treatment-resistant schizophrenia. Approximately 1% of patients experience potential life-threatening adverse effects in the form of agranulocytosis, greatly hindering its applicability in clinical practice. The etiology of clozapine-induced agranulocytosis (CIA) remains unclear, but is thought to be a heritable trait. We reviewed the genetic studies of CIA published thus far. One recurrent finding from early candidate gene study to more recent genome-wide analysis is that of the involvement of human leukocyte antigen locus. We conclude that CIA is most likely a complex, polygenic trait, which may hamper efforts to the development of a genetic predictor test with clinical relevance. To decipher the genetic architecture of CIA, it is necessary to apply more rigorous standards of phenotyping and study much larger sample sizes.
Indexed as
Identifiers
28418011What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.